Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

NCT03154697 · tracked via the Priya Life Science USA tracker

Sponsor

Vanda Pharmaceuticals

Phase

Observational

Started

2016-01

Last updated

2024-03-20

Condition(s) studied

Sleep Disturbances in Smith-Magenis Syndrome

Investigational drug(s) / intervention(s)

Data collection of sleep disturbances in individuals with SMS

Data collection of sleep disturbances in individuals with SMS: Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey

Study summary

This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.

Eligibility

Sex

ALL

Min age

3 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Parent or legal guardian of individual with Smith-Magenis Syndrome Exclusion Criteria: * Not legal guardian of individual with SMS

Primary outcome measure(s)

Number of individuals with Smith- Magenis syndrome — 5 years

Trial sites (1)

Facility	City	Region	Status
Vanda Pharmaceuticals	Washington D.C.	District of Columbia	Recruiting

More Vanda Pharmaceuticals trials in the USA

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Active, not recruiting

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder Active, not recruiting

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient Active, not recruiting

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Recruiting

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03154697 on ClinicalTrials.gov ↗ ← All trials in the USA